BioSpace News Archive

Dyve Biosciences, Inc. (“Dyve”) today announced the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute (“Moffitt”) showing preclinical data from the company’s unique delivery approach that unlocks the powerful effects of neutralizing the TME acidity.

Licensing agreement includes exclusive worldwide rights to develop and commercialize therapeutic and imaging applications for 3BP’s FAP-targeting technology; 3BP retains certain rights to develop FAP-targeted imaging agents

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”), a provider of scientifically-proven EMF modulation technology, announces the resignation of Jacinto Vieira effective immediately.

Nevro Corp. (NYSE: NVRO) today announced that it has enrolled the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, which is the first prospective randomized controlled trial (RCT) to assess restoration of neurological function as a primary objective in patients with intractable PDN.

Gilead Sciences recently released its inaugural Environmental, Social and Governance Impact Report.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced new data from VLTR-557, its long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong, M.D., has been invited to deliver the 2023 David Packard Award Lecture at the Uniformed Services University of the Health Sciences.

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced a program summary based on initial feedback from the U.S. Food & Drug Administration (“FDA”) on its Phase 3 FM program proposal featuring its lead development candidate IMC-1.

IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $150 million of shares of its common stock in an underwritten public offering.

Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals.